Baxter weighing options for Bielefeld plant

US healthcare company Baxter International is considering selling or restructuring its Bielefeld plant, Germany, by 2024.

The plant, which currently employs 700 people, produces cancer drugs and other injectable medicines.

Baxter has been under pressure to improve its profitability in recent years, and the sale or restructuring of the Bielefeld plant is part of a wider cost-cutting plan. The company has not yet made a final decision on the future of the plant, but it is expected to make an announcement in the coming months.

If Baxter does sell the plant, it would be a major blow to the local economy. The plant is one of the largest employers in Bielefeld, and its closure would have a significant impact on the city. However, Baxter has said that it is committed to working with the local community to find a solution that is best for all parties involved.